Search Results
Your search for The ,The matches 35552 pages
Showing 12051 - 12100Prognostic Model for Outcomes With Ibrutinib Treatment for Chronic Lymphocytic Leukemia
As reported in the Journal of Clinical Oncology, Ahn et al developed a four-factor model that identified risk groups for poorer outcomes among patients treated with ibrutinib for chronic lymphocytic leukemia. Study Details Patients treated with ibrutinib in phase II and III trials constituted the...
Research Into 'Cold' Tumors Heating Up in Pancreatic Cancer
Immunotherapy has changed the treatment paradigm for cancer, inducing durable responses in a subset of patients with previously refractory disease. However, current approaches are successful in only approximately 20% of cancers (so-called hot tumors). For the nearly 80% of cancers that are “cold”...
Can Routine Scans Help Predict Which Patients With Breast Cancer May Be at Risk for Heart Disease?
Automated analysis of the routine scans of patients with breast cancer may help to predict which women have a greater risk of developing cardiovascular disease, according to research presented by Gal et al at the 12th European Breast Cancer Conference (Abstract 7). Women who have been treated for...
Identifying Characteristics of Infused CAR T Cells Associated With Efficacy and Toxicity in Patients With Large B-Cell Lymphoma
Researchers have identified molecular and cellular characteristics of anti-CD19 chimeric antigen receptor (CAR) T-cell infusion products associated with how patients with large B-cell lymphoma respond to treatment and develop side effects. The research team also found that early changes in...
Oral Cancer Pain May Predict Likelihood of Metastasis
Oral cancer may be more likely to spread in patients experiencing high levels of pain, according to a team of researchers who found genetic and cellular clues as to why metastatic oral cancers are so painful. These findings were published by Bhattacharya et al in Scientific Reports. Researchers...
Biochemical Progression-Free Survival With Adjuvant vs Salvage Radiotherapy After Radical Prostatectomy: RADICALS-RT Trial
As reported in The Lancet by Christopher C. Parker, MD, and colleagues, initial findings in the phase III RADICALS-RT trial have shown no biochemical progression-free survival benefit and no difference in freedom from nonprotocol hormone therapy with adjuvant radiotherapy vs salvage radiotherapy...
Association of Adjuvant Chemotherapy With Survival in Early-Stage NSCLC: Do Tumor Size and High-Risk Features Have an Impact?
In a retrospective cohort study reported in JAMA Oncology, Pathak et al found that tumor size alone was not associated with improved survival with adjuvant therapy vs no adjuvant chemotherapy in patients with early-stage, node-negative non–small cell lung cancer (NSCLC). As stated by the...
Pulmonary Complication Rates After Elective Cancer Surgery in Hospitals With vs Without COVID-19–Free Surgical Pathways
In an international cohort study reported in the Journal of Clinical Oncology, Glasbey et al found that pulmonary complication rates after elective cancer surgery were lower in hospitals with vs without COVID-19–free surgical pathways during the COVID-19 pandemic. As stated by the investigators,...
Matti S. Aapro, MD, on Curing Sarcomas: An Expert Review
Matti S. Aapro, MD, of the Genolier Cancer Center, reviews the state of the science in sarcoma treatment: specialized surgery, disease diversity, emerging therapies, and the diagnostic approach to soft-tissue disease.
Making Strides in the Management of Pancreatic Cancer
The Special Conference on Pancreatic Cancer, sponsored by the American Association for Cancer Research (AACR) and held virtually this year, showcased cutting-edge discoveries and promising advances in the understanding and treatment of pancreatic cancer, reported by some of the world’s foremost...
FDA Pipeline: Designations for Treatments of Rare Blood Cancer, B-Cell Malignancies, and Gastric Cancers
Recently, the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation to an antibody-drug conjugate for the treatment of patients with relapsed or refractory blastic plasmacytoid dendritic cell neoplasm (BPDCN); gave Fast Track designation to a novel chimeric antigen...
New Study Finds Low Rates of Bone Mineral Density Testing in Men Treated With ADT for Prostate Cancer
A report published by Hu et al in JNCCN—Journal of the National Comprehensive Cancer Network found the rate of bone mineral density testing in people with prostate cancer undergoing androgen-deprivation therapy (ADT) has improved in recent years, but remains low. ADT is considered a cornerstone of...
NeoALTTO Trial: Final Analysis Examines Neoadjuvant Lapatinib/Trastuzumab in HER2-Positive Breast Cancer
Final analysis of results from a randomized clinical trial of lapatinib and trastuzumab given before surgery in patients with early HER2-positive breast cancer has found that women who had a pathologic complete response survived longer without cancer recurrence than patients who did not. This was...
Nab-paclitaxel vs Paclitaxel in Platinum-Refractory Metastatic Urothelial Cancer
In a phase II trial reported in JAMA Oncology, Srikala S. Sridhar, MD, MSc, FRCPC, and colleagues found no difference in progression-free survival with nab-paclitaxel vs paclitaxel in patients with platinum-refractory metastatic urothelial cancer. Study Details In the investigator-initiated...
Addition of Nivolumab to Neoadjuvant Chemotherapy in Resectable Stage IIIA NSCLC
In the Spanish phase II NADIM trial reported in The Lancet Oncology, Provencio et al found that the addition of nivolumab to neoadjuvant chemotherapy and the use of adjuvant nivolumab were associated with high 24-month rates of progression-free survival in patients with resectable stage IIIA...
Breast Cancer News From the ESMO Virtual Congress 2020
This week, we’ll be featuring our last disease-specific roundup from the ESMO Virtual Congress 2020. We’ll hear from three experts on their findings in breast cancer, focusing on results from two IMpassion trials as well as the efficacy of a novel antibody-drug conjugate in triple-negative disease, ...
Tell Your Patients About ASCO’s Oncologist-Approved Patient Information Website
ASCO believes that the best cancer care starts with the best cancer information. Its patient education website, Cancer.Net, gives patients and caregivers expertise and resources from ASCO in plain, easy-to-understand language so that they may make informed health-care decisions. Refer your patients ...
Unique Patient Identifiers Could Help Streamline Nation’s Health Information Technology Infrastructure
The Association for Clinical Oncology (ASCO) recently submitted comments to the Office of the National Coordinator for Health Information Technology (ONC) in response to its request for comments on improving patient identification and matching in the nation’s health information technology...
Conquer Cancer Announces 2020 Quality Care Symposium Merit Awards
Conquer Cancer, the ASCO Foundation® is pleased to announce the recipients of its 2020 Quality Care Symposium Merit Awards. These distinguished awards recognize oncology fellows and trainees who are first authors on top-ranking abstracts selected for presentation at the virtual ASCO Quality Care...
Bolder, More Aggressive Steps Needed to Achieve Cancer Care Equity
ASCO called for new actions to reduce disparities in cancer outcomes affecting racial and ethnic minorities, rural populations, sexual and gender minorities, people without insurance, and other disadvantaged populations. In a policy statement published in the Journal of Clinical Oncology (JCO),...
Conquer Cancer Offers New Research Grants Targeting Diversity in Research, Underserved Patients
The oncology workforce struggles with adequate representation of racial and ethnic minorities, with only 2.3% of practicing oncologists self-identifying as Black or African American and 5.8% of practicing oncologists self-identifying as Hispanic.1 Conquer Cancer, the ASCO Foundation® is offering a...
Art of Oncology: On the Page and in a Podcast, Personal Reflections From Oncologists Are a Fitting Companion Amid the COVID-19 Pandemic
The well-loved Art of Oncology section of the Journal of Clinical Oncology (JCO) and its pioneering podcast are both resonating as never before, as cancer specialists are prompted into deeper reflections about the poignant moments that give life meaning by the COVID-19 pandemic. JCO’s Art of...
Dana-Farber Opens Clinical Trial to Evaluate Simple Blood Test for Many Types of Cancer
Recent advances such as immune, cellular, and targeted therapies have provided new and effective means to treat a variety of cancers. Despite this considerable progress, cancer caught in its earliest stages remains the most curable. That is why Dana-Farber Cancer Institute is opening a new clinical ...
Surgical Oncologist Diane M. Simeone, MD, Strives to Improve Outcomes for Patients With Pancreatic Cancer
Despite decades of research and clinical advances, the diagnosis and treatment of pancreatic cancer remain formidable challenges. Recently, enormous efforts have been made to develop new methods for the early diagnosis and treatment of pancreatic cancer, such as those led by Diane M. Simeone, MD, a ...
Addition of Veliparib to Carboplatin/Paclitaxel in BRCA-Mutated Advanced Breast Cancer
As reported in The Lancet Oncology by Véronique Diéras, MD, of the Institut Curie, Paris, and Centre Eugène Marquis, Rennes, and colleagues, the phase III BROCADE3 trial has shown a significant improvement in progression-free survival with the addition of the poly (ADP-ribose) polymerase (PARP)...
Trends to Watch in Early-Onset Cancer Among Young Adults
Although cancer incidence and mortality rates for all cancers combined are considerably lower in younger adults than older adults, a disturbing pattern is beginning to emerge in the development of early-onset cancers, typically diagnosed in older patients, occurring in younger adults. The rising...
Pralsetinib for NSCLC With RET Gene Fusions
On September 4, 2020, pralsetinib (Gavreto) was granted accelerated approval by the U.S. Food and Drug Administration (FDA) for treatment of adults with metastatic RET fusion–positive non–small cell lung cancer (NSCLC) as detected by an FDA-approved test.1,2 The FDA simultaneously approved the...
A Leader in Drug Development, Patricia Keegan, MD, Reflects on Making a Difference in Cancer Care
In this installment of the Living a Full Life series, guest editor Jame Abraham, MD, spoke with Patricia Keegan, MD, who served at the U.S. Food and Drug Administration (FDA) for 30 years, most recently as Acting Associate Director of Medical Policy at the Oncology Center for Excellence (OCE)....
Dana-Farber Cancer Institute to Establish Benderson Family Program for Triple-Negative Breast Cancer
Dana-Farber Cancer Institute has received a $5 million gift from the Benderson Family of Sarasota, Florida, that will accelerate research in triple-negative breast cancer (TNBC) and strengthen Dana-Farber’s capabilities for treating this disease. The gift establishes the Benderson Family Program...
How Anxiety, Depression, and Low Social Support Impact the Intensity of Cancer Pain
Pain is one of the most common byproducts of cancer and its treatment. Tumors, surgery, intravenous chemotherapy, radiation therapy, targeted therapy, supportive care therapies (such as bisphosphonates), and diagnostic procedures can all cause pain in patients and may contribute to symptoms of...
Impact of Cytotoxic Chemotherapy Within 5 Weeks of COVID-19 Diagnosis in Patients With Cancer
In a single-institution study reported in the Journal of Clinical Oncology, Justin Jee, MD, PhD, of the Department of Medicine, Memorial Sloan Kettering Cancer Center (MSK), New York, and colleagues found that receipt of cytotoxic chemotherapy within 35 days of COVID-19 diagnosis in patients with...
Rucaparib Produces Durable Responses in Previously Treated Metastatic Castration-Resistant Prostate Cancer
As reported in the Journal of Clinical Oncology by Wassim Abida, MD, PhD, of Memorial Sloan Kettering Cancer Center, and colleagues, the phase II TRITON2 trial has shown that the poly (ADP-ribose) polymerase (PARP) inhibitor rucaparib produced durable responses in patients with previously treated...
Eliminating Routine Opioids While Maintaining Pain Control for Women Undergoing Lumpectomy or Excisional Biopsy
Changing from routinely prescribing opioids for patients who were having a lumpectomy or excisional biopsy to instead routinely prescribing nonsteroidal anti-inflammatory drugs [NSAIDs] resulted in a sharply decreased opioid prescription rate with “no difference in the proportion of patients...
Addition of Nelarabine to Standard Therapy Improves Disease-Free Survival in Newly Diagnosed T-Cell ALL
As reported in the Journal of Clinical Oncology by Kimberly P. Dunsmore, MD, of the Virginia Tech Carilion School of Medicine and Carilion Clinic, Roanoke, and colleagues, the phase III Children’s Oncology Group AALL0434 trial has shown that the addition of nelarabine to standard therapy improved...
Debbie’s Dream Foundation Launches New COVID-19 Resources and Support Program
Debbie’s Dream Foundation: Curing Stomach Cancer (DDF) recently announced its new COVID-19 Resources and Support Program. The program’s primary goal is to support, educate, and protect the already vulnerable stomach cancer community during the pandemic. The new initiative will help patients with...
Expert Point of View: Elizabeth Smyth, MD
The overall survival benefit for PD-L1 CPS ≥ 5 tumors in CheckMate 649 is a game-changer. An oxaliplatin doublet plus chemotherapy should become a standard of care for these patients,” according to Elizabeth Smyth, MD, an oncology consultant at Cambridge University Hospital NHS Foundation Trust in...
Nivolumab Plus Chemotherapy: New Standard of Care in Advanced Gastric Cancer?
As first-line treatment for advanced gastric cancer, nivolumab plus chemotherapy leads to significantly improved progression-free and overall survival over chemotherapy alone, investigators reported during a Presidential Symposium of the European Society for Medical Oncology (ESMO) Virtual Congress ...
Immunologist Thirumala-Devi Kanneganti, PhD, Receives NCI Outstanding Investigator Award
Thirumala-Devi Kanneganti, PhD, Vice Chair of the St. Jude Children’s Research Hospital Department of Immunology, has received a National Cancer Institute (NCI) Outstanding Investigator Award to build on her discoveries related to the innate immune system, inflammation, and cell death in health and ...
Carfilzomib and Daratumumab With Dexamethasone for Relapsed or Refractory Multiple Myeloma
On August 20, 2020, carfilzomib and daratumumab were approved for use in combination with dexamethasone for treatment of adults with relapsed or refractory multiple myeloma who have received one to three lines of therapy.1-3 Supporting Efficacy Data Approval was based on findings in two clinical...
Total Neoadjuvant Therapy for Pancreatic Adenocarcinoma
Patients with pancreatic adenocarcinoma who underwent total neoadjuvant therapy, consisting of chemotherapy followed by chemoradiation prior to surgery, had improved overall survival compared with those who had single-agent neoadjuvant therapy or surgery first, according to a large cohort study...
Expert Point of View: Johan Vansteenkiste, MD
Formal study discussant Johan Vansteenkiste, MD, of the University Hospitals KU Leuven, Belgium, commented on the ADAURA trial findings: “This is an impressive effect on disease-free survival [with osimertinib] and a very early snapshot of overall survival.” Dr. Vansteenkiste continued: “In the CNS ...
Impact of Adjuvant Osimertinib on CNS Recurrence of NSCLC: ADAURA Trial
Osimertinib significantly prolonged disease-free survival compared with placebo in patients with completely resected stage II to IIIA non–small cell lung cancer (NSCLC), according to the results of the large randomized phase III ADAURA trial presented at the European Society for Medical Oncology...
Expert Point of View: Rafal Dziadziuszko, MD
Commenting on the Lung ART study, Rafal Dziadziuszko, MD, a radiation oncologist from the Medical University of Gdansk, Poland, said: “Congratulations on this study to resolve the longest ongoing debate in thoracic oncology. For more than 20 years, we have been discussing whether to irradiate...
Study Questions Role of Routine Postoperative Radiotherapy in NSCLC With Mediastinal Nodes
The Lung ART trial was designed to demonstrate whether there is any benefit to the routine use of modern mediastinal postoperative radiotherapy in patients with non–small cell lung cancer (NSCLC) stage IIIA N2 (ie, patients with mediastinal nodal involvement) following complete resection and neo...
Expert Point of View: Camillo Porta, MD
Acknowledging there are now expanded therapeutic choices in the first-line setting for advanced renal cell carcinoma, formal study discussant Camillo Porta, MD, of the University of Bari Aldo Moro, Italy, said that studies of the immunotherapy combinations could not be compared directly. “We should ...
First-Line Nivolumab Plus Cabozantinib Improves Outcomes vs Sunitinib in Advanced Renal Cell Carcinoma
The combination of nivolumab plus cabozantinib was found to be superior to the former standard, sunitinib, in the first-line treatment of advanced or metastatic renal cell carcinoma, according to the results of the phase III CheckMate 9ER trial reported at the European Society for Medical Oncology...
A Primary Care Physician Explores Barriers to Cancer Prevention and Clinical Trial Accrual
To accelerate progress in the survival rates of people with cancer in the United States and to reduce cancer disparities across the entire spectrum of cancer from diagnosis to survivorship, there needs to be increased access to cancer screening and prevention programs. To shed light on this...
Mobilizing for Greater Equity in Health Care Despite the Challenges of COVID-19
The lockdown phase of the coronavirus (COVID-19) pandemic and continued measures, such as social distancing, while necessary, are disrupting cancer care in ways that will have consequences for months, if not years, to come. Studies are showing that delayed or suspended cancer treatments,...
Expert Point of View: George W. Sledge, Jr, MD
The results of monarchE were discussed by George W. Sledge, Jr, MD, Professor of Medicine and Chief of Oncology at Stanford University Medical Center, who offered some possibilities as to why its results were positive and those for palbociclib, in the phase III PALLAS trial, were “resoundingly...
Addition of Abemaciclib to Endocrine Therapy Reduces Recurrence in Early Breast Cancer
For the first time, an inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6) has reduced the risk of invasive disease recurrence in patients with early breast cancer when combined with standard endocrine therapy, investigators reported at the European Society for Medical Oncology (ESMO) Virtual...
